10 Most Profitable Blue Chip Stocks to Buy Now

5. Johnson & Johnson (NYSE:JNJ)

Net Profit Margin: 24.4%

Last year’s net income: $24.24 billion

Number of Hedge Fund Holders: 98

​Johnson & Johnson (NYSE:JNJ) is a leading healthcare company focusing on developing treatments in complex areas such as oncology, immunology, neuroscience, and cardiovascular health. The company is known for products such as Darzalex, Stelara, and Tremfya. Its MedTech segment offers medical devices across orthopaedics, surgery, and vision care. JNJ ranked eighth on our recent list of 10 Best Low Risk Stocks To Buy in 2025.

Johnson & Johnson (NYSE:JNJ) delivered strong operational sales growth of 4.2% across their business in Q1 2025, with YoY sales increases in both the innovative medicine and MedTech segments. This growth was particularly impressive as the company managed to achieve it despite facing an approximate 810 basis point headwind from the STELARA product and the impact of Part D redesign. In Innovative Medicine, eleven key brands grew double digits, with DARZALEX continuing to set standards in multiple myeloma with over 20% growth and quarterly sales exceeding $3 billion.

Looking ahead, 2025 is positioned as a catalyst year that will set up accelerated growth through the second half of the decade and beyond. Johnson & Johnson (NYSE:JNJ) strengthened its portfolio through strategic moves, including the completion of the Intra-Cellular Therapies acquisition and a commitment to invest more than $55 billion in US manufacturing, R&D, and technology over the next four years. The company also demonstrated confidence in its future by increasing its dividend for the 63rd consecutive year and maintaining its adjusted reported earnings per share guidance of 6.2% at the midpoint, despite various headwinds, including tariffs. With more than $24 billion in net income generated in the latest fiscal year, JNJ is one of the most profitable blue-chip stocks on our list.